CSNK1α1 mediates malignant plasma cell survival

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Multiple myeloma (MM) is a hematologic malignancy with limited therapeutic options.
• Proteasome inhibitors are a standard MM treatment, but resistance can develop.
• Novel therapeutic targets are needed to overcome resistance and improve patient outcomes.

Purpose of the Study:

• To investigate the role of casein kinase 1-alpha1 (CSNK1α1) in multiple myeloma (MM).
• To evaluate CSNK1α1 inhibition as a potential therapeutic strategy for MM, including bortezomib-resistant cases.
• To explore the involvement of CSNK1α1 in MM initiation and progression.

Main Methods:

• CSNK1α1 expression analysis in MM cell lines and patient samples.
• Inhibition of CSNK1α1 using D4476 and small hairpin RNAs (shRNAs).
• Cell cycle analysis, apoptosis assays, and cytotoxicity studies in MM cells.
• In vivo studies using mouse models of MM and oncogene-induced tumors.

Main Results:

• CSNK1α1 is expressed in MM cells and its inhibition induces G0/G1 arrest, G2/M arrest, and apoptosis.
• CSNK1α1 inhibition demonstrates cytotoxicity in bortezomib-resistant MM cells and enhances bortezomib efficacy.
• CSNK1α1 signaling pathways involve CDKN1B, P53, and FADD, with affected gene signatures including interferon-α and tumor necrosis factor-α.
• CSNK1α1 reduction prevents oncogene-induced cell transformation and tumor development in mice.

Conclusions:

• Targeting CSNK1α1 represents a novel therapeutic strategy for multiple myeloma (MM), distinct from proteasome inhibition.
• Combined inhibition of CSNK1α1 and bortezomib may enhance treatment efficacy in MM.
• CSNK1α1 inhibition could potentially prevent the progression from monoclonal gammopathy of undetermined significance (MGUS) to MM.